Horbinski C, Berger T, Packer RJ, Wen PY. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol. 2022;18.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl J Med. 2005;352:987–96.

Article  PubMed  CAS  Google Scholar 

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.

Article  PubMed  CAS  Google Scholar 

Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21:V1–100.

Article  PubMed  PubMed Central  Google Scholar 

Stupp R, Lukas RV, Hegi ME. Improving survival in molecularly selected glioblastoma. Lancet. 2019;393:615–7.

Article  PubMed  Google Scholar 

Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. the polymer-brain tumor treatment Group. Lancet. 1995;345:1008–12.

Article  PubMed  CAS  Google Scholar 

Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15:2887–93.

Article  PubMed  Google Scholar 

Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79–88.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Iuchi T, Inoue A, Hirose Y, Morioka M, Horiguchi K, Natsume A, et al. Long-term effectiveness of Gliadel implant for malignant glioma and prognostic factors for survival: 3-year results of a postmarketing surveillance in Japan. Neurooncol Adv. 2022;4.

Xing WK, Shao C, Qi ZY, Yang C, Wang Z. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis. Drug Des Devel Ther. 2015;9:3341–8.

PubMed  PubMed Central  CAS  Google Scholar 

Roux A, Caire F, Guyotat J, Menei P, Metellus P, Pallud J. Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. Neurochirurgie. 2017;63:433–43.

Article  PubMed  CAS  Google Scholar 

Ius T, Cesselli D, Isola M, Toniato G, Pauletto G, Sciacca G, et al. Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas. Curr Treat Options Neurol. 2018;20.

Bai P. Biology of poly(ADP-Ribose) polymerases: the factotums of cell maintenance. Mol Cell. 2015;58:947–58.

Article  PubMed  CAS  Google Scholar 

Masutani M, Fujimori H. Poly(ADP-ribosyl)ation in carcinogenesis. Mol Asp Med. 2013;34:1202–16.

Article  CAS  Google Scholar 

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.

Article  PubMed  CAS  Google Scholar 

Farmer H, McCabe H, Lord CJ, Tutt AHJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.

Article  PubMed  CAS  Google Scholar 

Disilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41:609–17.

Article  PubMed  CAS  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl J Med. 2017;377:523–33.

Article  PubMed  CAS  Google Scholar 

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl J Med. 2019;381:317–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;382:2091–102.

Article  PubMed  Google Scholar 

Fulton B, Short SC, James A, Nowicki S, McBain C, Jefferies S, et al. PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clin Transl Radiat Oncol. 2018;8:12–6.

PubMed  Google Scholar 

Ghorai A, Mahaddalkar T, Thorat R, Dutt S. Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence. Cancer Lett. 2020;490:44–53.

Article  PubMed  CAS  Google Scholar 

Sim H wen, Galanis E, Khasraw M. PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers (Basel). 2022;1–16.

Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. 2020;22:1840–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, et al. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer. 2019;19.

Verhagen CVM, De Haan R, Hageman F, Oostendorp TPD, Carli ALE, O’Connor MJ, et al. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015;116:358–65.

Article  PubMed  CAS  Google Scholar 

’t Hart E, Bianco J, Bruin MAC, Derieppe M, Besse HC, Berkhout K, et al. Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. J Controlled Release. 2023;357:287–98.

Article  Google Scholar 

Khang M, Lee JH, Lee T, Suh HW, Lee S, Cavaliere A, et al. Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. Sci Transl Med. 2023;15.

Rahman C V., Smith SJ, Morgan PS, Langmack KA, Clarke PA, Ritchie AA, et al. Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix. PLoS One. 2013;8.

Smith SJ, Tyler BM, Gould T, Veal GJ, Gorelick N, Rowlinson J, et al. Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste. Clin Cancer Res. 2019;25:5094–106.

Article  PubMed  CAS  Google Scholar 

McCrorie P, Mistry J, Taresco V, Lovato T, Fay M, Ward I, et al. Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours. European Journal of Pharmaceutics and Biopharmaceutics. 2020;157.

Muresan P, McCrorie P, Smith F, Vasey C, Taresco V, Scurr DJ, et al. Development of nanoparticle loaded microneedles for drug delivery to a brain tumour resection site. Eur J Pharm Biopharm. 2023;182:53–61.

Article  PubMed  CAS  Google Scholar 

McCrorie P, Rowlinson J, Scurr DJ, Marlow M, Rahman R. Detection of Label-Free Drugs within Brain Tissue Using Orbitrap Secondary Ion Mass Spectrometry as a Complement to Neuro-Oncological Drug Delivery. Pharmaceutics. 2022;14.

Smith SJ, Rowlinson J, Estevez-Cebrero M, Onion D, Ritchie A, Clarke P, et al. Metabolism-based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential. Neurooncol Adv. 2020;2.

Andrieux G, Das T, Griffin M, Straehle J, Paine SML, Beck J, et al. Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence. Genome Med. 2023;15:48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24:679–86.

Article  PubMed  CAS  Google Scholar 

Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharm. 1997;39:383–9.

Article  CAS  Google Scholar 

Shapira-Furman T, Serra R, Gorelick N, Doglioli M, Tagliaferri V, Cecia A, et al. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. J Controlled Release. 2019;295:93–101.

Article  CAS  Google Scholar 

Wicks RT, Azadi J, Mangraviti A, Zhang I, Hwang L, Joshi A, et al. Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. Neuro Oncol. 2015;17:70–80.

Article  PubMed  CAS